$6.38
-0.51 (-7.40%)
Open$6.86
Previous Close$6.89
Day High$7.42
Day Low$6.21
52W High$20.00
52W Low$5.12
Volume—
Avg Volume34.8K
Market Cap22.10M
P/E Ratio—
EPS$-14.44
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+469.4% upside
Current
$6.38
$6.38
Target
$36.33
$36.33
$21.56
$36.33 avg
$42.60
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.14M | 4.29M | 4.24M |
| Net Income | -270,468 | -254,054 | -270,426 |
| Profit Margin | -6.5% | -5.9% | -6.4% |
| EBITDA | -483,031 | -431,767 | -494,923 |
| Free Cash Flow | -204,723 | -222,413 | -294,472 |
| Rev Growth | -4.9% | +3.8% | -2.6% |
| Debt/Equity | 0.13 | 0.14 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |